Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TPH1 | P17752 | 15/20 | 0.36 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.33 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.32 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.32 |
| ▸ | TPH2 | Q8IWU9 | 1/20 | 0.32 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.32 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.32 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.32 |
| ▸ | LTC4S | Q16873 | 1/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30494530 | 1.00 | TPH1 (0.36) | TPH1HRH4FFAR1FFAR4TPH2 | |
| SCHEMBL30494553 | 0.93 | TPH1 (0.37) | TPH1HRH4FFAR1FFAR4TPH2 | |
| SCHEMBL24253748 | 0.93 | TPH1 (0.37) | TPH1HRH4FFAR1FFAR4TPH2 | |
| SCHEMBL30494551 | 0.89 | TPH1 (0.36) | TPH1HRH4FFAR1FFAR4TPH2 | |
| SCHEMBL24253852 | 0.87 | TPH1 (0.37) | TPH1HRH4FFAR1FFAR4TPH2 | |
| SCHEMBL30423886 | 0.87 | TPH1 (0.37) | TPH1HRH4FFAR1FFAR4TPH2 | |
| SCHEMBL24253649 | 0.86 | TPH1 (0.35) | TPH1TPH2 | |
| SCHEMBL24253760 | 0.84 | TPH1 (0.41) | TPH1TPH2 | |
| SCHEMBL24253761 | 0.84 | TPH1 (0.41) | TPH1TPH2 | |
| SCHEMBL24253553 | 0.84 | TPH1 (0.41) | TPH1TPH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11708366-B2 | Heteroaryl substituted spiropiperidinyl derivatives and pharmaceutical uses thereof | NOVARTIS AG (CH) | 2023-07-25 | — | — | US | disclosed |
| US-11708366-B2 | Heteroaryl substituted spiropiperidinyl derivatives and pharmaceutical uses thereof | NOVARTIS AG (CH) | 2023-07-25 | — | — | US | disclosed |
| US-20220048909-A1 | HETEROARYL SUBSTITUTED SPIROPIPERIDINYL DERIVATIVES AND PHARMACEUTICAL USES THEREOF | NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, INC. | 2022-02-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11708366-B2 | Heteroaryl substituted spiropiperidinyl derivatives and pharmaceutical uses thereof | REN, NR3C2, PKD1 | TPH1 3142/4885HRH4 590/4885FFAR1 1838/4885 |
| US-20220048909-A1 | HETEROARYL SUBSTITUTED SPIROPIPERIDINYL DERIVATIVES AND PHARMACEUTICAL USES THEREOF | REN, NR3C2, PKD1 | TPH1 3142/4885HRH4 590/4885FFAR1 1838/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.